Disclosure statement: The authors have declared no conflicts of interest.

Jochen Wacker1, Rene Handschu2, Berhard Manger1, Georg Schett1, Jochen Zwerina1

1Department of Internal Medicine 3 and Institute for Clinical Immunology and 2Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany

Accepted 5 June 2009

Correspondence to: Jochen Zwerina, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany. E-mail: jochen.zwerina@uk-erlangen.de


Rheumatology 2009;48:1174–1176
doi:10.1093/rheumatology/kep210
Advance Access publication 20 July 2009

Lateral medullary syndrome with anti-neuronal antibodies (anti-Ta/Ma2) in primary Sjögren’s syndrome

Sir, A 61-year-old Irish female with known primary SS, presented to the emergency department with a 3-h history of sudden-onset vertigo, vomiting, diplopia, ataxia and hemi-facial sensory loss. She had a long-standing history of polyarthralgia and sicca symptoms with a hypergammaglobulinaemia (IgG 25g/l) and positive ANA, anti-Ro and anti-La antibodies and therefore met the diagnostic criteria for SS. Six months earlier she had an acute psychotic episode secondary to cerebral vasculitis with cerebrospinal fluid (CSF) oligoclonal bands and three small hyperintense foci in the frontal lobe on MRI of the brain. Past medical history included Grave’s disease, immune thrombocytopenic purpura and coeliac disease. She admitted to poor compliance with prescribed HCQ (400 mg daily), mycophenolate mofetil (MMF) (500 mg twice daily), prednisolone (5 mg daily) and olanzepine (2.5 mg daily). On examination, she was alert and orientated. There was sensory loss to all modalities on the left side of her face and right leg, left-sided cerebellar signs (nystagmus, dysmetria, dysdiadokokinesis and truncal ataxia) and a left Horner’s syndrome, consistent with a left lateral medullary syndrome.

Haematological, biochemical and inflammatory indices were within normal limits (ESR 27, CRP <5). CSF exhibited no evidence of infection. Serology demonstrated high titres of ANA, anti-Ro and anti-La antibodies. LAC, aCL and anti-dsDNA antibodies were absent. Serum western blotting for anti-neuronal antibodies was strongly positive for the anti-paraneoplastic Ma2 (PNMA2, also known as anti-Ma2/Ta) antibody only. Anti-aquaporin4 antibodies—associated with Devic’s disease and recently suggested as a myelopathic association of SS—were negative [1].

MRI brain revealed two discrete foci of high signal intensity in the left medulla and left cerebellar hemisphere (Fig. 1). These were thought to be due to cerebral vasculitis rather than thromboembolism, given a normal echocardiogram and absence of aPLs. Despite the presence of anti-Ma2/Ta antibodies, a malignancy screen (CT chest, abdomen and pelvis, mammography, tumour markers, serum electrophoresis and urine Bence Jones protein) did not reveal evidence of neoplasia. There were no clinical or radiological features suggestive of lymphoma.

The patient was treated with intravenous methylprednisolone (500mg) for 5 days and six courses of cyclophosphamide (1 g/kg...
Paraneoplastic neurological syndromes (PNS) are remote effects of malignancy on the nervous system. New diagnostic criteria for PNS have been proposed which include six onconeuronal antibodies: anti-Hu, Yo, Ri, CV2, amphiphysin and Ma2/Ta antibodies, that indicate the presence of a ‘definite’ PNS, even in the absence of a detectable tumour (Table 1) [6]. There have been 36 reported cases of patients with anti-Ma2/Ta antibodies; however, their significance in the context of autoimmunity is unclear. We have described a case of lateral medullary syndrome secondary to cerebral vasculitis associated with SS and positive anti-neuronal antibodies (anti-Ma2/Ta), who remains well at 1-year follow-up with no evidence of malignancy and will continue to be monitored.

The spectrum of CNS-SS may include the lateral medullary syndrome and may be associated with anti-neuronal antibodies in the apparent absence of neoplasia.

**Disclosure statement:** The authors have declared no conflicts of interest.

**Rheumatology key message**

- The spectrum of CNS-SS may include the lateral medullary syndrome and may be associated with anti-neuronal antibodies in the apparent absence of neoplasia.

**Fig. 1.** MRI of the brain: (a) axial and (b) sagittal sections. Two foci of high signal intensity are seen in the left medulla (dashed arrow) and left cerebellar hemisphere (white arrow).

<table>
<thead>
<tr>
<th>Anti-neuronal</th>
<th>Molecular weight, kDa</th>
<th>Paraneoplastic neurological syndrome</th>
<th>Tumour</th>
</tr>
</thead>
<tbody>
<tr>
<td>anti-Hu (ANNA 1)</td>
<td>35–38</td>
<td>Cerebellar syndrome, encephalomyelitis, sensory neuropathy</td>
<td>SCLC</td>
</tr>
<tr>
<td>anti-Yo (PCA 1)</td>
<td>34, 52 and 62</td>
<td>Cerebellar syndrome</td>
<td>Ovary, breast</td>
</tr>
<tr>
<td>Anti-Ri (ANNA 2)</td>
<td>55 and 80</td>
<td>Opsoclonus, cerebellar syndrome, brainstem encephalomyelitis</td>
<td>Breast, SCLC, gynaecological</td>
</tr>
<tr>
<td>anti-CV2 (CRMP5)</td>
<td>66</td>
<td>Encephalomyelitis, sensory neuropathy</td>
<td>SCLC, thymoma</td>
</tr>
<tr>
<td>anti-Amphiphysin</td>
<td>128</td>
<td>Stiff person syndrome, encephalomyelitis</td>
<td>Breast, SCLC</td>
</tr>
<tr>
<td>anti-Ma (Ma1) (PNMA 1 or 2)</td>
<td>37 and 40</td>
<td>Cerebellar syndrome, brainstem encephalomyelitis</td>
<td>Various</td>
</tr>
<tr>
<td>anti-Ta (Ma2) (PNMA 2)</td>
<td>40</td>
<td>Limbic encephalitis, cerebellar syndrome, brainstem encephalomyelitis</td>
<td>Testicular</td>
</tr>
</tbody>
</table>

SCLC: small cell lung cancer; ANNA 1 or 2: anti-neuronal nuclear antibody type 1 or 2; PCA1: anti-Purkinje cell antibody type 1; CRMP 5: collapsin response mediator protein type 5; PNMA 1 or 2: paraneoplastic Ma2 antigen type 1 or 2.
Rheumatology 2009;48:1176–1177
doi:10.1093/rheumatology/kep201
Advance Access publication 13 July 2009

Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate

Sir, With great interest we read the article of Lee et al. [1] in which associations between candidate polymorphisms and disease activity in RA patients on MTX were assessed. Hereby, the minor allele of the single nucleotide polymorphism (SNP) within the ATIC gene (rs4673993), which is in linkage disequilibrium (LD) with rs2372536, was associated with low disease activity [28-joint disease activity score (DAS28) ≤3.2] in a cohort of patients on MTX monotherapy. Previously, our group found an opposite association between disease activity at baseline and treatment effect of MTX on DAS28 over time and that hereby no account.

We agree with the authors that applying the Bonferroni correction is conservative. In general, multiple corrections are focused on a certain chosen level of significance. However, the reporting of effect size and confidence interval (CI) may be more informative than the blunt P-values. Regarding pharmacogenetics in RA and adequate sample size, a mean decrease in DAS for a specific genetic variant of 1.2 with a 95% CI of 0.8, 1.6 illustrates a range of values for what the mean decrease might be if the entire population could be studied instead of just the sample. Generally, estimated effect sizes and CIs are more informative about application of findings than statistical outcomes, like P-values. Consequently, a clinician becomes more involved into the results of a pharmacogenetic study and could evaluate its own clinical decision-making in, for example, additive value of genotyping patients based on these estimates.

Only a small number of studies have been performed concerning rs4673993 and/ or rs2372536 in the ATIC gene and MTX therapy outcome. Therefore, replication, (idealy) meta-analyses and performance of prospective study design in large cohorts are warranted to demonstrate the legitimate predictive value of these variants for assessment of disease activity and/or treatment outcome on MTX.

Disclosure statement: T.W.J.H. is co-inventor on a patent that predicts patient responsiveness on MTX. H.-J.G. holds patents EP 06119819.8 and US 60/840,973 related to a pharmacogenetic prediction model for MTX. He is also a consultant for Cypress Bioscience, San Diego, USA and for PGx Health, Newton (MA), USA. All other authors have declared no conflicts of interest.

WOUTER M. KOOLOOS1, HENK-JAN GUCHELAAR1, TOM W. J. HUIZINGA2, JUDITH A. M. WESSELS1

1Department of Clinical Pharmacy and Toxicology and 2Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
Accepted 9 June 2009

Correspondence to: Judith A. M. Wessels, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600, NL 2300 RC, Leiden, The Netherlands. E-mail: j.a.m.wessels@lumc.nl